You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for MT-7117


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug MT-7117?

MT-7117 is an investigational drug.

There have been 12 clinical trials for MT-7117. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2020.

The most common disease conditions in clinical trials are Protoporphyria, Erythropoietic, Sclerosis, and Scleroderma, Systemic. The leading clinical trial sponsors are Mitsubishi Tanabe Pharma Development America, Inc., Mitsubishi Tanabe Pharma Corporation, and Mitsubishi Tanabe Pharma America Inc.

There is one US patent protecting this investigational drug.

Recent Clinical Trials for MT-7117
TitleSponsorPhase
INcreased Sun Exposure Without Pain In Research Participants With EPP or XLPMitsubishi Tanabe Pharma America Inc.Phase 3
Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy SubjectsMitsubishi Tanabe Pharma Development America, Inc.Phase 1
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)Mitsubishi Tanabe Pharma Development America, Inc.Phase 3

See all MT-7117 clinical trials

Clinical Trial Summary for MT-7117

Top disease conditions for MT-7117
trials011223344Protoporphyria, ErythropoieticSclerosisScleroderma, SystemicScleroderma, Diffuse[disabled in preview]
Top clinical trial sponsors for MT-7117
trials01234567891011Mitsubishi Tanabe Pharma Development America, Inc.Mitsubishi Tanabe Pharma CorporationMitsubishi Tanabe Pharma America Inc.[disabled in preview]

See all MT-7117 clinical trials

US Patents for MT-7117

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
MT-7117 ⤷  Subscribe Pyrrolidine compound and application as melanocortin receptor agonist Mitsubishi Tanabe Pharma Corp ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 1 of 1 entries

MT-7117: A Promising Drug Candidate for Rare Phototoxicity Disorders

Introduction

MT-7117, also known as dersimelagon, is a synthetic, non-peptide small molecule that has been gaining significant attention for its potential in treating rare phototoxicity disorders, specifically erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). Developed by Mitsubishi Tanabe Pharma Corporation, this drug candidate has advanced to Phase 3 clinical trials, marking a crucial milestone in its development journey.

Mechanism of Action

MT-7117 acts as a selective agonist of the melanocortin 1 receptor (MC1R). This receptor plays a critical role in the body's response to UV light, and its activation can help mitigate the severe pain and phototoxicity associated with EPP and XLP[3][5].

Clinical Development

Phase 2 Trials

The Phase 2 clinical trial for MT-7117 involved 102 patients with EPP and was designed as a randomized, double-blind, placebo-controlled study. The trial included a two-week screening period, a 16-week double-blind treatment period, and a six-week follow-up period. This study assessed the efficacy, safety, and tolerability of MT-7117, providing valuable insights that have informed the design of the subsequent Phase 3 trials[5].

Phase 3 Trials

In June 2020, Mitsubishi Tanabe Pharma initiated a Phase 3 clinical trial for MT-7117 in the U.S. This global, multicenter, randomized, double-blind, placebo-controlled study aims to evaluate the efficacy, safety, and tolerability of MT-7117 in approximately 159 patients (aged 12-75 years) with EPP or XLP over a 26-week treatment period. The primary objective is to investigate the efficacy of MT-7117 on the time to first onset of prodromal symptoms associated with sunlight exposure[3][5].

Regulatory Designations

MT-7117 has received several significant regulatory designations that underscore its potential and the urgency of addressing the needs of patients with EPP and XLP. These include:

  • Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) on June 8, 2020, which recognizes the drug's potential to treat rare diseases.
  • Fast Track Designation by the FDA in June 2018, which expedites the development and review process for drugs that treat serious conditions and fill an unmet medical need[5].

Market Projection

Given the progress in clinical trials and the regulatory support, MT-7117 is poised to make a significant impact in the market for treatments of EPP and XLP.

Unmet Medical Need

EPP and XLP are rare genetic disorders characterized by severe phototoxicity, leading to painful reactions upon exposure to sunlight. Current treatments are limited, and patients often have to adopt strict lifestyle modifications to avoid sunlight, which can significantly impact their quality of life. MT-7117 addresses this unmet need by offering a potential therapeutic option that could increase pain-free light exposure[5].

Market Potential

The orphan drug designation and fast track status indicate a favorable regulatory environment, which can accelerate the drug's approval process. If approved, MT-7117 could capture a significant share of the market for EPP and XLP treatments due to its unique mechanism of action and the lack of effective alternatives.

Competitive Landscape

The market for treatments of rare phototoxicity disorders is relatively niche but growing. MT-7117's entry could disrupt this space by offering a more targeted and effective treatment option. The drug's success would depend on its efficacy, safety profile, and the ability of Mitsubishi Tanabe Pharma to effectively market and distribute the drug to the targeted patient population.

Future Outlook

As MT-7117 progresses through its Phase 3 trials, several factors will influence its future outlook:

  • Clinical Trial Outcomes: Positive results from the ongoing Phase 3 trials will be crucial for regulatory approval and market acceptance.
  • Regulatory Approvals: Successful navigation of the regulatory process, including potential approvals in various countries, will determine the drug's global reach.
  • Market Adoption: The drug's adoption by healthcare providers and patients will depend on its demonstrated efficacy, safety, and the overall patient experience.

Long-Term Extension Studies

In addition to the Phase 3 trials, Mitsubishi Tanabe Pharma is also conducting long-term extension studies to evaluate the safety and tolerability of MT-7117 over an extended period. These studies are essential for providing comprehensive data on the drug's long-term effects and will be critical for post-marketing surveillance and potential label expansions[4].

Conclusion

MT-7117 represents a promising advancement in the treatment of EPP and XLP, offering hope to patients who have limited therapeutic options. With its selective MC1R agonist mechanism, favorable regulatory designations, and ongoing Phase 3 trials, this drug candidate is well-positioned to make a significant impact in the market.

Key Takeaways

  • Mechanism of Action: MT-7117 acts as a selective agonist of the melanocortin 1 receptor (MC1R).
  • Clinical Trials: The drug is currently in Phase 3 clinical trials for EPP and XLP.
  • Regulatory Designations: Orphan Drug Designation and Fast Track Designation by the FDA.
  • Market Potential: Addresses a significant unmet medical need with limited current treatment options.
  • Future Outlook: Depends on positive clinical trial outcomes, regulatory approvals, and market adoption.

FAQs

What is MT-7117 used for?

MT-7117 is being developed as a treatment for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), rare genetic disorders characterized by severe phototoxicity.

What is the mechanism of action of MT-7117?

MT-7117 acts as a selective agonist of the melanocortin 1 receptor (MC1R), which helps mitigate the severe pain and phototoxicity associated with EPP and XLP.

What stage of clinical development is MT-7117 in?

MT-7117 is currently in Phase 3 clinical trials.

Has MT-7117 received any regulatory designations?

Yes, MT-7117 has received Orphan Drug Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA).

What are the key outcomes being measured in the Phase 3 trials of MT-7117?

The primary objective of the Phase 3 trials is to investigate the efficacy of MT-7117 on the time to first onset of prodromal symptoms associated with sunlight exposure in patients with EPP or XLP.

Who is developing MT-7117?

MT-7117 is being developed by Mitsubishi Tanabe Pharma Corporation.

Sources

  1. GlobalData, "Dersimelagon Phosphate in Systemic Sclerosis (Scleroderma) - LOA Innovation and Trend Analysis".
  2. GlobalData, "Dersimelagon Phosphate in Porphyria (Erythropoietic Protoporphyria) - LOA Innovation and Trend Analysis".
  3. Drug Discovery News, "MT-7117 begins Phase 3 for phototoxicity".
  4. Patsnap Synapse, "Dersimelagon - Patsnap Synapse".
  5. Mitsubishi Tanabe Pharma America, "Phase-3 Clinical Trial of MT-7117 Initiated in the U.S. for Rare Diseases Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)".

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.